MX2022007464A - Composiciones biofarmaceuticas y metodos relacionados. - Google Patents

Composiciones biofarmaceuticas y metodos relacionados.

Info

Publication number
MX2022007464A
MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A
Authority
MX
Mexico
Prior art keywords
related methods
biopharmaceutical compositions
compositions
biopharmaceutical
antagonism
Prior art date
Application number
MX2022007464A
Other languages
English (en)
Spanish (es)
Inventor
Kelly Neelon
Mingxuan Zhang
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2022007464A publication Critical patent/MX2022007464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2022007464A 2019-12-18 2020-12-10 Composiciones biofarmaceuticas y metodos relacionados. MX2022007464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US201962950595P 2019-12-19 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
MX2022007464A true MX2022007464A (es) 2022-06-27

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007464A MX2022007464A (es) 2019-12-18 2020-12-10 Composiciones biofarmaceuticas y metodos relacionados.

Country Status (11)

Country Link
US (1) US20230059341A1 (cg-RX-API-DMAC10.html)
EP (1) EP4077388A1 (cg-RX-API-DMAC10.html)
JP (2) JP2023507981A (cg-RX-API-DMAC10.html)
KR (1) KR20220129548A (cg-RX-API-DMAC10.html)
CN (1) CN115298218A (cg-RX-API-DMAC10.html)
AU (2) AU2020407007A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022014694A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164600A1 (cg-RX-API-DMAC10.html)
IL (1) IL293753A (cg-RX-API-DMAC10.html)
MX (1) MX2022007464A (cg-RX-API-DMAC10.html)
WO (1) WO2021126657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355757A1 (en) * 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
EP4626927A1 (en) * 2022-11-30 2025-10-08 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies
EP4763222A1 (en) * 2025-08-25 2026-06-24 Qilu Pharmaceutical Co., Ltd. A composition comprising apitegromab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3357508A4 (en) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
KR20220129548A (ko) 2022-09-23
CA3164600A1 (en) 2021-06-24
IL293753A (en) 2022-08-01
AU2020407007A1 (en) 2022-06-23
JP2026027328A (ja) 2026-02-18
EP4077388A1 (en) 2022-10-26
CN115298218A (zh) 2022-11-04
WO2021126657A1 (en) 2021-06-24
JP2023507981A (ja) 2023-02-28
AU2025203823A1 (en) 2025-06-19
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
CO2019012080A2 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
UY37957A (es) Moduladores de la vía de estrés integrada
UY37956A (es) Moduladores de la vía de estrés integrada
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
UY37958A (es) Moduladores de la vía de estrés integrada
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CO2017010618A2 (es) Anticuerpos contra icos
JOP20200177A1 (ar) طرق علاج السرطان باستخدام الأجسام المضادة anti-pd-1 المناهضة
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
BR112022011629A2 (pt) Anticorpos biespecíficos caninizados para tratar dermatite atópica
UY37230A (es) Moduladores de la vía de estrés integrada
UY37231A (es) Moduladores de la vía de estrés integrada
UY37228A (es) Moduladores de la vía de estrés integrada
MX2019005277A (es) Composiciones de celulas t con car anti-bcma.
MX2017000985A (es) Anticuerpos anti-pd-1.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.